Opthea Limited: Promising Outlook with Sozinibercept in wAMD and Pivotal Trials on Track
Leerink Partners analyst Marc Goodman has maintained their bullish stance on OPT stock, giving a Buy rating yesterday.Invest with Confidence: ...
Why active management outsmarts stock market turbulence
Active management in mutual funds proves its worth during market downturns. During the recent correction in the Nifty 50 ...
Microsoft Q2 Earnings: Why I'm Bullish Despite Capex Concerns
Microsoft delivered a strong earnings report that investors didn't celebrate, as the stock sold off 5%. Read why I remain ...
XBI: Diverse Holding Amid Strong Catalysts, Buy
Invest in SPDR S&P Biotech ETF (XBI) for long-term growth potential and diverse, equal-weighted portfolio in the biotech ...
MarketWatch5 天
Simple 60/40 portfolio would’ve easily beaten hedge-fund returns last year
A simple 60/40 portfolio model would’ve easily beaten the returns that hedge-fund investors enjoyed, according to an estimate of their performance. Barclays estimated the weighted average ...